Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Thursday

Key Points

• Arrowhead Pharmaceuticals is set to release its Q3 2025 earnings data on Thursday, August 7th, with analysts expecting a loss of ($0.94) per share and revenue of $29.01 million.
• The company recently reported significant earnings exceeding estimates, with revenue of $542.71 million and an EPS of $2.75 for the previous quarter, far outpacing analyst expectations.
• Institutional investors have shown increased interest, with Goldman Sachs boosting its stake by 34.6%, and institutional ownership now standing at 62.61% of the company's stock.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) is expected to be releasing its Q3 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.94) per share and revenue of $29.01 million for the quarter.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same period in the prior year, the business posted ($1.02) earnings per share. On average, analysts expect Arrowhead Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Stock Performance

ARWR traded up $0.64 during midday trading on Monday, hitting $16.57. 509,253 shares of the company were exchanged, compared to its average volume of 1,886,712. The company's 50 day simple moving average is $16.43 and its 200 day simple moving average is $16.06. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.31. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $27.34. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -11.86, a price-to-earnings-growth ratio of 18.74 and a beta of 0.94.

Analyst Ratings Changes

Several research firms have recently issued reports on ARWR. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Chardan Capital reiterated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Finally, HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.71.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC boosted its holdings in Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after buying an additional 979 shares in the last quarter. Focus Partners Wealth boosted its holdings in Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company's stock worth $207,000 after buying an additional 15,123 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Arrowhead Pharmaceuticals during the first quarter worth about $514,000. Royal Bank of Canada boosted its holdings in Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company's stock worth $576,000 after buying an additional 10,496 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after buying an additional 447,456 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.